Showing 4621-4630 of 5910 results for "".
- Sight Sciences Files Lawsuit Against Ivantis for Patent Infringementhttps://modernod.com/news/sight-sciences-files-lawsuit-against-ivantis-for-patent-infringement/2480283/Sight Sciences announced that it has filed a lawsuit in the United States District Court in Delaware against Ivantis for infringement of U.S. Patents that describe and claim devices and methods for reducing intraocular pressure in the eye. The patents are Numbers 8,287,48
- Visus Unveils Additional Ophthalmic Drug Candidates for Corneal Wound Healing, Glaucoma and AMDhttps://modernod.com/news/visus-unveils-additional-ophthalmic-drug-candidates-for-corneal-wound-healing-glaucoma-and-amd/2480276/During its inaugural Capital Markets Day in New York City, Visus Therapeutics unveiled additional ophthalmic drug candidates with applications in development for corneal wound healing, glaucoma and age-related macular degeneration (AMD). Additionally, the company introduced a novel drug
- Outlook Therapeutics Presents Positive NORSE THREE Safety Data for Lytenava (bevacizumab-vikg)https://modernod.com/news/outlook-therapeutics-presents-positive-norse-three-safety-data-for-lytenava-bevacizumab-vikg-at-euretina/2479575/Outlook Therapeutics announced the presentation of safety data from the NORSE THREE trial evaluating ONS-5010/Lytenava (bevacizumab-vikg) at the EURETINA Virtual 2021 conference on September 12, 2021. The previously announced topline results from the open-label safety study demonstrated that
- AbbVie Makes Large Investment in Regenxbio's Gene Therapy for Retinal Diseaseshttps://modernod.com/news/abbvie-and-regenxbio-announce-eye-care-collaboration/2479577/AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and other chronic retinal diseases. RGX-314 is currently being evaluated in patient
- World Council of Optometry Launches Myopia Management Online Resourcehttps://modernod.com/news/world-council-of-optometry-launches-myopia-management-online-resource/2479506/Building upon their efforts to establish a standard of care for myopia management, the World Council of Optometry (WCO) and CooperVision have jointly developed an easy-to-use online resource that provides multilingual assets and approaches that will enable busy eye care professionals—regardless o
- NIH-Funded Robotic Cane With 3D Camera Can Accurately Guide User to Chosen Locationhttps://modernod.com/news/nih-funded-robotic-cane-with-3d-camera-can-accurately-guide-user-to-chosen-location/2479504/Equipped with a color 3D camera, an inertial measurement sensor, and its own on-board computer, a newly improved robotic cane could offer blind and visually impaired users a new way to navigate indoors. When paired with a building’s architectural drawing, the device can accurately guide a user to
- Apellis Reports Mixed Phase 3 Results for Geographic Atrophy Drug; Will Pursue FDA Approvalhttps://modernod.com/news/apellis-announces-topline-results-from-phase-3-derby-and-oaks-studies-in-geographic-atrophy/2479503/Apellis Pharmaceuticals reported topline results from the phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). B
- ProQR Announces Axiomer RNA Editing Licensing and Research Collaboration with Lillyhttps://modernod.com/news/proqr-announces-axiomer-rna-editing-licensing-and-research-collaboration-with-lilly/2479498/ProQR Therapeutics, the developer of RNA therapies for the treatment of genetic eye diseases, announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in
- TearClear Files IND Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solutionhttps://modernod.com/news/tearclear-files-ind-application-to-begin-its-clinical-trial-for-tc-002-latanoprost-ophthalmic-solution/2479495/TearClear has filed an investigational new drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution 0.005%. Approximately 30%-40% of patients who rely on preserved, chronic glaucoma therapies show signs of moderat
- Pixium Vision Expands Collaboration with Stanford University On Next Generation Prima System Implantshttps://modernod.com/news/pixium-vision-expands-collaboration-with-stanford-university-on-next-generation-prima-system-implants/2479492/Pixium Vision SA announced the expansion of a collaboration with academic partner Stanford University to develop the second generation of implants for its bionic vision Prima System for dry age-related macular degeneration (AMD). “We are very excited to be extending our collaboration with